Esperion Therapeutics | ESPR - Assets


Esperion Therapeutics reported $465.89M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amarin USD 670.78M 10.96M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cipla INR 401.64B 27.77B Sep/2025
CSL USD 37.9B 1.5B Dec/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Geron USD 570.54M 3.16M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 12.34B 203M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025